Novel Promising Therapeutic Agents in Multiple Sclerosis

Author(s): Abbas Mirshafiey.

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 1 , Issue 3 , 2007

Become EABM
Become Reviewer

Abstract:

Multiple sclerosis (MS) is the most common chronic demyelinating disease of the central nervous system, which causes progressive neurological disability. Over the recent decade, there has been an impressive accumulation of data about novel designed immunosuppressive and anti-inflammatory agents promising for treating MS and its animal model, experimental autoimmune encephalomyelitis. Regarding, disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive phase of this disease, novel promising therapeutic strategies could open a light horizon in approaching to an efficient treatment in MS. This review provides a compilation of the more thoroughly studied of these novel immunotherapeutic agents and new aspects of designed molecular targets and patents which have recently evolved.

Keywords: Multiple sclerosis, experimental autoimmune encephalomyelitis, immunosuppressive, anti-inflammatory, immunotherapy, molecular targets

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 1
ISSUE: 3
Year: 2007
Page: [218 - 224]
Pages: 7
DOI: 10.2174/187221307782418856
Price: $58

Article Metrics

PDF: 1